Medical Breakthroughs

Healthcare AI Exits: The SPAC Reckoning for Investors

Listen to this article · 6 min listen

The whole conversation around healthcare AI exits has changed. The speculative gold rush is over, and now we’re having much more sober discussions based on actual financial performance. If you’re an investor trying to figure out this space, you have to understand how these companies get to the public markets and, more importantly, what happens after they arrive. The Special Purpose Acquisition Company (SPAC) route, which felt like a magic carpet to an IPO for a while, is now just another case study we can measure and compare.

The SPAC Gateway to Nasdaq

Butterfly Network, the digital ultrasound and imaging company, famously used a SPAC merger to get onto the public markets. The whole idea behind a SPAC was to offer a simpler, faster way to get liquid and raise capital compared to a traditional IPO slog. Butterfly pulled it off, listing on Nasdaq, the go-to exchange for tech companies. Getting that public listing was a huge step, turning a private company into a publicly traded one that has to live with the constant scrutiny and transparency of the market. During their peak, the appeal of SPACs was obvious. They seemed like an efficient way for companies in hot sectors like healthcare AI to grab a lot of capital and a wide investor base without the pain of endless roadshows and regulatory hoops. For a company like Butterfly, whose whole game is a digital ultrasound gizmo with AI analysis layered on top, the speed of a SPAC felt right for the breakneck pace of an AI-native business.

Early Backing and the Digital Imaging Thesis

Of course, Butterfly’s journey to a public company didn’t just start with the SPAC. Back when it was private, it pulled in serious backing from VCs, most famously from Khosla Ventures. That early money was what let them build and actually sell their digital ultrasound and imaging tech in the first place. Khosla, which has a reputation for betting on disruptive tech, saw the potential in a portable ultrasound device you could carry in your pocket. Wasn’t that the whole point? The bet resonated with the big-picture idea of making healthcare diagnostics cheaper and more accessible for everyone. The investment thesis was pretty clear: launch a wedge product into the imaging market, build a massive data moat from all the scans being done everywhere, and then use that data to build out even better AI for diagnostics. Moving from a giant, clunky ultrasound cart to a handheld device that connects to your phone was a massive jump, promising to bring diagnostics to places way outside the hospital. Getting that early nod from a big-name investor showed the market and the tech itself had legs.

Revenue Realities Post-Merger

The real test of any public listing, whether it’s an old-school IPO or a SPAC, is what the financial performance looks like afterward. Butterfly’s post-merger numbers give investors real data to chew on when they’re thinking about the SPAC path. The company reported fiscal 2025 revenue of $97.6 million, a 19 percent jump from the year before. SEC EDGAR filings for Butterfly Network For fiscal 2026, they’ve bumped their revenue guidance up to between $119 million and $123 million, which would be about 22% to 26% growth. While that shows growth, the raw number gives us a concrete benchmark to measure against all the hype that usually comes with a SPAC deal. This is where an investor’s real work begins. The 19 percent growth suggests they’re getting their device into more hands. But you have to look at that number in the context of the entire healthcare AI market and who they’re competing against. When we’re evaluating these outcomes, we dig into a few things. How good is the clinical validation for the tech? That directly affects doctor adoption and how deep you can get with payers. What’s the regulatory risk rating, something a company can improve by getting 510(k) clearance or even a De Novo classification? And finally, is there published outcomes data showing the thing actually works and saves money in the real world? That’s what you need for reimbursement and long-term revenue. Even though Butterfly has its FDA clearances, like the one for its Gestational Age (GA) blind-sweep AI tool in early 2026, the revenue is the main scorecard now that it’s a public company. FDA 510(k) database

The SPAC Chapter: A Comparator, Not a Template

Butterfly Network’s trip through a SPAC merger and its revenue performance on Nasdaq is an excellent case study for anyone thinking about exit strategies in healthcare AI. The SPAC chapter is now officially a source of comparison data. It’s not a template you just copy. The original promise of getting to public capital fast has been checked by the tough reality of market performance and intense investor scrutiny. For investors comparing ways to go public, the takeaway is simple: the novelty has worn off the SPAC, and it’s been replaced by a hard focus on results you can actually measure. Any company wanting to go public, and any investor looking at them, has to ask if the chosen path really helps the business grow and create value over the long haul. The ability to generate real, sustainable revenue, backed by a high clinical validation score, a good regulatory risk profile, and solid payer penetration, is still what separates winners from losers. The Butterfly experience shows that while there are different roads to the public market, the fundamentals of a good investment, strong tech, a clear market need, sharp execution, and numbers to back it up, never change. As the healthcare AI field grows up, the focus will just keep getting sharper on the companies that can deliver on those metrics, no matter how they chose to list.

Frequently Asked Questions

What is the primary difference between a SPAC merger and a traditional IPO for healthcare AI companies seeking to go public?

A SPAC merger offers a streamlined and faster path to public markets compared to a traditional IPO. It promises quicker liquidity and capital infusion, often bypassing the protracted roadshows and stringent regulatory scrutiny associated with conventional IPOs.

What are some key factors investors consider when evaluating the financial performance of a healthcare AI company post-listing, regardless of the listing route?

Investors scrutinize the company’s revenue figures and growth rates, comparing them against initial projections. They also consider the clinical validation score of the technology, the regulatory risk rating (e.g., FDA clearances), and published outcomes data demonstrating real-world efficacy and cost-effectiveness.

How did Butterfly Network perform financially after its SPAC merger?

Butterfly Network reported fiscal 2025 revenue of $97.6 million, a 19 percent year-over-year increase. For fiscal year 2026, the company raised its revenue guidance to a range of $119 million to $123 million, representing approximately 22% to 26% growth.

Is the SPAC route still considered a viable template for healthcare AI companies looking to go public?

No, the article states that the SPAC chapter is now definitively a comparator rather than a template. The initial promise of rapid access to public capital has been tempered by the realities of market performance and increased investor scrutiny.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Healthcare AI Investor Guide is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.